. Furthermore, some patients with BRAF V600E-mutant melanoma or NSCLC and almost all patients with BRAF V600E-mutant colorectal or thyroid cancer do not initially respond to BRAF inhibitor therapy [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] [14] [15] . Similarly, MAPK pathway inhibition with MEK inhibitor therapy is largely ineffective in individuals with mutant RAS because of primary resistance [5] [6] [7] 16, 17 . Thus, there is an urgent need to uncover the molecular targets that limit the response to RAFand MEK-targeted therapy in both BRAF-and RAS-mutant tumors to develop new therapeutic strategies to enhance treatment response and patient survival.
l e t t e r s
Resistance to RAF-and MEK-targeted therapy is a major clinical challenge [1] [2] [3] [4] . RAF and MEK inhibitors are initially but only transiently effective in some but not all patients with BRAF gene mutation and are largely ineffective in those with RAS gene mutation because of resistance [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Through a genetic screen in BRAF-mutant tumor cells, we show that the Hippo pathway effector YAP (encoded by YAP1) acts as a parallel survival input to promote resistance to RAF and MEK inhibitor therapy. Combined YAP and RAF or MEK inhibition was synthetically lethal not only in several BRAF-mutant tumor types but also in RAS-mutant tumors. Increased YAP in tumors harboring BRAF V600E was a biomarker of worse initial response to RAF and MEK inhibition in patients, establishing the clinical relevance of our findings. Our data identify YAP as a new mechanism of resistance to RAF-and MEK-targeted therapy. The findings unveil the synthetic lethality of combined suppression of YAP and RAF or MEK as a promising strategy to enhance treatment response and patient survival.
Oncogenic activation of RAF-MEK-ERK (mitogen-activated protein kinase (MAPK) pathway) signaling frequently occurs in human cancers, often through somatic activating mutations in BRAF or RAS genes. MAPK pathway-targeted therapies (RAF and MEK inhibitors) have been deployed in patients with BRAF-and RAS-mutant tumors and have been demonstrated to have clinical efficacy in melanoma and non-small cell lung cancer (NSCLC) harboring BRAF V600E [1] [2] [3] [4] , but responses are variable, incomplete and transient because of resistance [1] [2] [3] [4] . Furthermore, some patients with BRAF V600E-mutant melanoma or NSCLC and almost all patients with BRAF V600E-mutant colorectal or thyroid cancer do not initially respond to BRAF inhibitor therapy [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] [14] [15] . Similarly, MAPK pathway inhibition with MEK inhibitor therapy is largely ineffective in individuals with mutant RAS because of primary resistance [5] [6] [7] 16, 17 . Thus, there is an urgent need to uncover the molecular targets that limit the response to RAFand MEK-targeted therapy in both BRAF-and RAS-mutant tumors to develop new therapeutic strategies to enhance treatment response and patient survival.
To uncover new genetic modifiers of the response to RAFtargeted therapy in human cancer, we conducted a pooled short hairpin RNA (shRNA) screen in human NSCLC cells harboring BRAF V600E (HCC364 cells) that are dependent on oncogenic BRAF for growth 11 . Our goal was to identify genes that, when silenced, enhanced the response to RAF inhibitor. We screened 27,500 shRNAs targeting 5,046 signaling components (Supplementary Table 1) . After infecting HCC364 cells with lentiviruses expressing the shRNA library and subjecting them to selection, we treated the cells with the selective BRAF inhibitor vemurafenib or with vehicle control (Fig. 1a) . We quantified the abundance of each barcoded hairpin to identify shRNAs that were selectively depleted during treatment with vemurafenib but not vehicle (Fig. 1a) , as described previously 12, 18 . The Hippo signaling pathway component YAP1 was the best-scoring hit in the screen, as all six YAP1-targeted shRNAs present in the screening library were depleted during treatment with vemurafenib but not vehicle (Fig. 1b,c, Supplementary Fig. 1 and Supplementary Table 2 ).
We therefore hypothesized that the encoded YAP protein is a new determinant of the response to RAF inhibitor and that YAP inhibition might enhance the efficacy of RAF-targeted therapy.
We used independent shRNAs to knock down YAP1 in HCC364 cells. YAP1 silencing enhanced sensitivity to vemurafenib with little effect in vehicle-treated cells, confirming the initial screening results (Fig. 1d,f, Supplementary Fig. 1 and Supplementary Table 3) . As BRAF activates MEK and MEK inhibitor monotherapy has incomplete efficacy in patients with BRAF V600E-mutant tumors 1,3 , we tested whether YAP1 silencing enhanced the response to MEK inhibitor in HCC364 cells. YAP1 knockdown enhanced sensitivity to the MEK inhibitor trametinib in this system (Fig. 1e,f and Supplementary  Table 3 ). YAP1 suppression enhanced not only sensitivity to trametinib (IC 50 , half-maximal inhibition concentration) but also the degree to which maximal growth inhibition was achieved by MEK inhibition (Fig. 1e and Supplementary Table 4) . These effects of YAP1 silencing were specific to targeted inhibition of RAF-MEK signaling, as YAP1 knockdown had no effect on sensitivity to cytotoxic chemotherapy (Supplementary Fig. 2 ). We found that the transcriptional output of YAP is likely critical for regulation of the response to RAF-and MEK-targeted therapy, as silencing either of the Hippo-YAP pathway transcription factor effectors TEAD2 and TEAD4 (encoding TEA domain (TEAD) family members 2 and 4) 19, 20 phenocopied the effects of YAP1 suppression on sensitivity to RAF and MEK inhibitors in HCC364 cells (Supplementary Fig. 2 ). Moreover, we observed nuclear YAP expression in these BRAF-mutant cells in cellular fractionation studies (Supplementary Fig. 3 ). We further found that stable overexpression of either YAP1 or its paralog TAZ 19 substantially decreased sensitivity to vemurafenib and trametinib in HCC364 cells (Supplementary Fig. 4) .
As MEK inhibitor therapy is more effective than RAF inhibitor therapy in some tumor cells with non-V600E forms of mutant BRAF 11 , we tested whether YAP1 silencing enhanced sensitivity to trametinib l e t t e r s npg l e t t e r s in Cal-12T human NSCLC cells that exhibit MEK-ERK activation but harbor a BRAF mutation encoding a G466V substitution. YAP1 depletion enhanced the efficacy of the MEK inhibitor in Cal-12T cells, indicating that the effects of YAP1 suppression in response to MEK inhibitor are not restricted to V600E forms of mutant BRAF ( Fig. 1g and Supplementary Tables 3 and 4) . Collectively, these data demonstrate that YAP modulates the response to targeted inhibition of RAF signaling in human NSCLC models. We next investigated whether YAP regulates the response to targeted inhibition of BRAF signaling in other BRAF-mutant tumor histologies, using human melanoma, colon and thyroid cancer cell lines with endogenous BRAF mutation encoding the V600E substitution. YAP1 suppression enhanced the efficacy of both vemurafenib and trametinib in the A2058 and WM793 melanoma cell lines, the HT29 and WiDr colon cancer cell lines, and the KHM-5M and HTC/C3 thyroid cancer cell lines, all harboring BRAF V600E, without significantly affecting vehicle-treated cells (Fig. 2a,b, Supplementary Figs. 3, 5 and 6, and Supplementary Tables 3 and 4). We again observed nuclear YAP expression in these other BRAF-mutant cell lines ( Supplementary  Fig. 3 ). Extending our in vitro findings, we found that silencing YAP1 enhanced the response to not only vemurafenib but also trametinib in vivo in A2058 melanoma xenografts, without significantly affecting tumor growth in vehicle-treated tumors ( Fig. 2c and Supplementary Fig. 7 ). YAP1 suppression led to tumor regression upon trametinib treatment in this in vivo system ( Fig. 2c and Supplementary Fig. 7 ). Additionally, we found that YAP1 silencing enhanced the response to RAF and MEK inhibitors in vivo in HT29 colon cancer xenografts harboring BRAF V600E, without significantly affecting tumor growth in vehicle-treated tumors ( Fig. 2d and Supplementary Fig. 7 ). These data show that YAP1 suppression enhances RAF and MEK inhibitor efficacy in many BRAF-mutant tumor types, not only in cells with intrinsic sensitivity but also in those with intrinsic resistance to monotherapy with RAF or MEK inhibitor (Fig. 2, Supplementary Figs. 5, 6 and 7, and Supplementary Tables 3 and 4). YAP1 silencing even overcame intrinsic resistance to RAF and MEK inhibitors in A2058 and KHM-5M cells in which no effect from inhibition of epidermal growth factor receptor (EGFR), which can promote resistance to RAF inhibitor in some tumors with BRAF V600E 8, 12 , was observed ( Supplementary Fig. 8 ). These data indicate a distinct and broad role for YAP in promoting resistance to RAF and MEK inhibition across a wide spectrum of BRAF-mutant tumors.
We next explored whether YAP regulates the response to MAPK pathway inhibition in tumor cells with oncogenic RAS, which drives tumor growth, in part, through MEK-ERK signaling 21 . No effective targeted therapies exist for patients with tumors having mutant RAS, with MEK inhibitor therapy exhibiting limited efficacy [5] [6] [7] 16, 17 . We investigated whether YAP1 suppression could enhance the response to MEK inhibitor in RAS-mutant tumors. Silencing YAP1 enhanced the efficacy of trametinib in multiple KRAS-and NRAS-mutant human NSCLC, melanoma and pancreatic adenocarcinoma models and across several distinct mutant alleles of RAS genes (Fig. 2e npg l e t t e r s Supplementary Figs. 5, 9 and 10, and Supplementary Tables 3 and 4). YAP1 suppression enhanced the response to trametinib, as measured by IC 50 across these models, but had only modest effects on maximal growth inhibition upon MEK inhibitor treatment in RASmutant melanoma and pancreatic adenocarcinoma cells ( Fig. 2e and Supplementary Fig. 5 ). We again observed nuclear YAP expression in these RAS-mutant cell lines (Supplementary Fig. 3 ). We confirmed these findings in vivo by demonstrating that YAP1 silencing enhanced the response to trametinib in MOR/CPR xenograft tumors encoding KRAS G12C ( Fig. 2f and Supplementary Fig. 7 ). These data identify combined inhibition of YAP and MEK as a promising strategy to enhance treatment response in patients with mutant RAS. Supplementary Fig. 11 ). These findings show the synthetic lethality of combined suppression of YAP and RAF-MEK signaling.
We reasoned that YAP might enhance the expression of an antiapoptotic factor to promote survival and resistance to RAF and MEK inhibitors. YAP can transcriptionally upregulate the expression of specific antiapoptotic components, including the BCL2 family member protein BCL-xL (encoded by BCL2L1) in some cell types 27 . Therefore, we hypothesized that YAP might control the threshold for apoptosis induction during RAF-and MEK-targeted therapy by promoting BCL-xL expression as a parallel survival input in tumor cells with oncogenic BRAF. Indeed, YAP1 suppression resulted in decreased expression of BCL-xL, specifically in the context of treatment with either vemurafenib or trametinib in HCC364 NSCLC, A2058 melanoma, HT29 colon cancer and KHM-5M thyroid cancer cells ( Fig. 3i and Supplementary Fig. 12 ). These data show that YAP and RAF-MEK signaling function in parallel to regulate BCL-xL levels, which might ensure that the threshold for the induction of apoptosis is achieved only with inhibition of both YAP and RAF-MEK signaling.
We confirmed the relevance of BCL-xL function downstream of YAP, establishing that BCL-xL overexpression rescued the effect Figure 4 Increased YAP levels in human tumor specimens encoding BRAF V600E is a biomarker of worse response to RAF inhibitor in patients. (a) Quantification of the levels of YAP in human NSCLC (n = 13) and melanoma (n = 29) specimens encoding BRAF V600E, KRAS-mutant NSCLC specimens (n = 23) and human tumor specimens with wild-type BRAF and KRAS (WT; NSCLC; n = 14), as measured by immunohistochemistry with a validated antibody to YAP and scoring of the staining as low, intermediate or high. (b) Quantification of YAP levels in melanoma or NSCLC specimens encoding BRAF V600E from patients with either a confirmed complete response (melanoma CR, n = 6) or an incomplete response (melanoma IR, n = 29; NSCLC IR, n = 5; incomplete response includes either a partial response or stable disease by RECIST criteria) to initial treatment with a BRAF inhibitor (vemurafenib, dabrafenib or LGX818; n = 16) or to combined RAF and MEK inhibitor treatment (dabrafenib and trametinib or LGX818 and MEK162; n = 19) (P = 0.008 distinguishing the proportion of complete response from incomplete response among melanomas with high YAP levels). YAP immunohistochemistry analysis was conducted as in a. (c) YAP functions via BCL-xL as a parallel input to suppress apoptosis and promote survival, protecting BRAF-and RAS-mutant tumor cells from death (left). RAF-and MEK-targeted therapy is therefore ineffective or cytostatic, resulting in an incomplete tumor response (middle). YAP suppression lowers the threshold for the induction of apoptosis upon RAF or MEK inhibition, promoting a complete response (right). P, phosphorylation; RAS*, mutant RAS.
Our findings extend recent studies indicating that YAP regulates KRAS oncogene dependence in some tumor types [22] [23] [24] by establishing that YAP1 suppression enhances the response to MEK inhibitor in multiple tumor histologies and functions across several different forms of oncogenic MAPK signaling.
We next investigated the mechanism through which YAP regulates the response to RAF-and MEK-targeted therapy. As YAP1 silencing profoundly impaired cell viability, specifically upon treatment with RAF or MEK inhibitor, and previous work indicates that YAP can regulate apoptosis 22, [24] [25] [26] , we reasoned that suppression of YAP together with RAF-MEK signaling might be synthetically lethal. Indeed, we found that YAP1 knockdown promoted apoptosis, as measured by both the induction of caspase-3 and caspase-7 activity and PARP cleavage, upon treatment with either RAF or MEK inhibitor that alone was insufficient to induce apoptosis in NSCLC (Fig. 3a,b) , melanoma (Fig. 3c,d ), colon cancer (Fig. 3e,f and Supplementary Fig. 11 ) and thyroid cancer (Fig. 3g,h ) models harboring BRAF V600E. YAP1 silencing also enhanced apoptosis upon treatment with MEK inhibitor, which by itself did not induce cell death in RAS-mutant NSCLC models, albeit more modestly than in many BRAF-mutant models npg l e t t e r s of YAP1 silencing on the response to RAF and MEK inhibitors in HCC364 cells (Supplementary Fig. 13 ). These data indicate that BCL-xL is a critical effector by which YAP promotes resistance to RAF or MEK inhibition. Consistent with these observations and those of others 28 , pharmacological BCL-xL inhibition using ABT-263 (navitoclax) enhanced the efficacy of treatment with either RAF or MEK inhibitor in several tumor cell lines harboring BRAF V600E, including NSCLC (HCC364), melanoma (A2058) and colon cancer (HT29) models (Fig. 3j) . Treatment with BCL-xL inhibitor also enhanced sensitivity to trametinib in RAS-mutant NSCLC cells ( Supplementary  Fig. 11 ). These effects of ABT-263 treatment were phenocopied by treatment with another BCL-xL inhibitor, TW37 ( Supplementary  Fig. 11 ). These data indicate that YAP acts as a parallel survival input via BCL-xL to promote resistance to RAF and MEK inhibitors, extending recent findings linking BCL-xL with the response to MEK inhibitor in some KRAS-mutant tumors 29, 30 .
To further explore the synthetic lethal relationship between YAP and RAF or MEK inhibition, we conducted unbiased transcriptional profiling in HCC364 cells harboring BRAF V600E in which YAP and MEK were suppressed individually or concurrently. These profiling data showed few significant changes in gene expression with silencing of YAP1 alone (adjusted P value < 0.05 and at least 40% decreased or at least 66% increased expression, compared to the control) (Supplementary Table 5 ), consistent with our functional studies indicating that YAP1 silencing has a weaker impact on cell viability ( Fig. 1 and Supplementary Fig. 1 ). Treatment with trametinib led to differential expression of more genes, consistent with the important role of BRAF-MEK signaling in these cells (Supplementary Table 5 ). Silencing YAP1 together with trametinib treatment similarly led to differential expression of a substantial number of genes, with evidence of coregulation of some genes, including BCL2L1 (Supplementary Table 5 ). Pathway analysis of the genes that were significantly altered specifically by combined inhibition of YAP and MEK (such as BCL2L1) indicated an enrichment of genes involved in apoptosis (Supplementary Fig. 14) . These findings offer additional insight into the role of BCL-xL and the synthetic lethality of simultaneous suppression of YAP and RAF-MEK signaling.
We next sought to determine the clinical relevance of our findings. We hypothesized that YAP might be upregulated in some BRAFor RAS-mutant human tumors and that this upregulation might promote resistance to RAF and MEK inhibitors in patients. We therefore measured YAP levels in primary human tumor specimens obtained from patients with NSCLC (n = 13) or melanoma (n = 35) encoding BRAF V600E, from patients with KRAS-mutant NSCLC (n = 23) or from patients with NSCLC with wild-type BRAF and KRAS (n = 14). We observed high levels of YAP in the majority of the tumors encoding BRAF V600E (NSCLC and melanoma) and the KRAS-mutant NSCLC tumors and lower levels of YAP in tumors with wild-type BRAF and KRAS (NSCLC), as measured by immunohistochemistry using an antibody to YAP (Fig. 4a and Supplementary  Fig. 15 ). These data show that YAP is upregulated in some BRAFand RAS-mutant human tumors. As MEK inhibitor monotherapy is largely ineffective in patients with KRAS-mutant tumors 17 , these findings suggest that increased YAP levels in these tumors might contribute to primary resistance to MEK inhibition.
We next assessed whether YAP expression was inversely correlated with the initial response to RAF and MEK inhibition in patients with BRAF V600E (n = 35). We measured YAP levels by immunohistochemistry in melanoma specimens harboring BRAF V600E from patients (n = 35) with either a confirmed complete response or an incomplete response (including either a partial response or stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria) to monotherapy with a BRAF inhibitor (vemurafenib, dabrafenib or LGX818; n = 16) or to combined RAF and MEK inhibitor treatment (dabrafenib and trametinib or LGX818 and MEK162; n = 19). Patients with melanoma harboring BRAF V600E who had a complete response to therapy exhibited lower YAP expression in the pretreatment tumor samples (Fig. 4b and Supplementary Table 6) . Conversely, patients who had an incomplete response to therapy had higher YAP expression in the baseline tumor samples (Fig. 4b  and Supplementary Table 6 ). We also analyzed YAP expression in NSCLC tumors with BRAF V600E obtained from patients (n = 5) before investigational treatment with dabrafenib, which resulted in an incomplete response in each patient. All but one of these pretreatment NSCLC specimens exhibited high YAP expression (Fig. 4b and Supplementary Table 6 ). Taken together, these data suggest that increased YAP levels are a biomarker of decreased response to RAF or MEK inhibitor in patients with BRAF-mutant tumors.
We also assessed YAP levels in melanomas obtained from patients at the time of progression on RAF or MEK inhibitor therapy after an initial response to test the hypothesis that YAP might contribute to acquired resistance. We examined YAP expression by immunohistochemistry in an additional 32 paired melanoma specimens with BRAF V600E obtained from 16 patients both before RAF or MEK inhibitor treatment and upon the development of acquired resistance. As the majority of the pretreatment melanoma specimens encoding BRAF V600E from patients harbored high baseline YAP levels (Supplementary Table 7) , we examined whether YAP levels were higher at the time of progression in the subset of patients whose pretreatment tumors had low or intermediate YAP levels (25%, 4/16 cases; Supplementary Fig. 15 and Supplementary Table 7) . We found increased YAP levels in each paired tumor obtained at acquired resistance in comparison to the matched pretreatment specimen (Supplementary Fig. 15 and Supplementary Table 7) . These findings further suggest that increased YAP levels might limit the clinical efficacy of RAF and MEK inhibitors.
All together, our findings unveil the synthetic lethality of concurrent inhibition of YAP and RAF-MEK signaling (Fig. 4c) and augment findings indicating an emerging role for YAP in tumorigenesis across several different tumor types [22] [23] [24] 31, 32 . The data show unanticipated functional cross-talk between YAP and RAF-MEK signaling. Our findings uncover a new, promising polytherapeutic strategy to enhance the efficacy of RAF and MEK inhibitors and survival in patients with a broad range of BRAF-and RAS-mutant tumors.
METHOdS
Methods and any associated references are available in the online version of the paper. shRNA screen with the DECIPHER shRNA library. Lentiviral plasmids encoding shRNAs including the Cellecta DECIPHER shRNA library human module 1 are described online at the company's website. shRNA lentiviruses were generated from HEK293FT cells according to the manufacturer's protocol (Cellecta). HCC364 cells were infected with lentiviral supernatant containing shRNAs with a multiplicity of infection (MOI) of 0.3. After 48 h, the infection rate was measured by flow cytometry, and cells were replated with medium containing 1 µg/ml puromycin. Seventy-two hours after the addition of puromycin, 27 million cells were frozen for further analysis, and 27 million cells were replated in the presence and absence of 1 µM or 3 µM vemurafenib; the medium was refreshed every 3 d for 10 d. Genomic DNA was isolated, and shRNA inserts were retrieved according to the manufacturer's protocol (Cellecta). Indexes and adaptors for deep sequencing were incorporated into PCR primers. Sample quantification was performed on a Bioanalyzer (Agilent Technologies) to ensure that samples were pooled at the same quantity. Deep sequencing was performed using the Illumina HiSeq 2500 platform at the Center for Advanced Technology of the University of California, San Francisco. shRNA barcodes were segregated and deconvoluted from each sequencing read. P values for each gene were calculated as follows. For this sample, we set N at 10,000. Individual shRNAs used for the validation experiments were purchased from Sigma.
RNA deep sequencing and analysis. RNA from each of the indicated cell lines was extracted by RNeasy kit (Qiagen). In total, 2 µg of total RNA was used for deep sequencing library preparation using Illumina TruSeq sample prep kits according to the manufacturer's protocols. Sequencing libraries with different indices were pooled and sequenced in paired-end format to a length of 100 bp using the HiSeq 2500 platform at the Center for Advanced Technology at the University of California, San Francisco. Reads were aligned against NCBI Build 37 (hg19) of the human genome using NCBI Ensembl transcript annotation (version 75) with RSEM 35 , which also yielded gene-level quantification of expression.
Differential expression and pathway analysis. Differential gene expression analysis was performed with DESeq 36 among three sets of conditions: (i) YAP1 knockdown using two independent validated shRNAs, (ii) shSCR (scrambled shRNA control) and trametinib (100 nM), and (iii) YAP1 knockdown using two independent shRNAs and trametinib (100 nM), each compared to the control condition (shSCR and DMSO). Pathway analysis (gene set enrichment) was performed on genes significantly differentially expressed (q < 0.05) that were exclusive to the YAP1 knockdown and trametinib treatment condition, using MSigDB 37 .
